TABLE 1.
Characteristics of Wet OAB Versus Non-OAB Cohorts
| Patient Characteristic | Total N = 2,146 | Non-Treatment-Regimen Failures n = 1,255 | Treatment-Regimen Failures n = 891 | Difference P Valuea |
|---|---|---|---|---|
| Demographics (at index) | ||||
| Age at index | 0.350 | |||
| Mean (SD) | 45.1 (13.21) | 44.9 (12.93) | 45.5 (13.60) | - |
| Gender, n (%) | < 0.001 | |||
| Male | 1,185 (55.2) | 766 (61.0) | 419 (47.0) | - |
| Female | 961 (44.8) | 489 (39.0) | 472 (53.0) | - |
| Primary payer, n (%) | 0.061 | |||
| Commercial | 2,012 (93.8) | 1,187 (94.6) | 825 (92.6) | - |
| Medicare | 134 (6.2) | 68 (5.4) | 66 (7.4) | - |
| Clinical characteristics (pre-index) | ||||
| Comorbidities, n (%)b | ||||
| Anxiety | 123 (5.7) | 61 (4.9) | 62 (7.0) | 0.039 |
| Cerebrovascular disease | 37 (1.7) | 15 (1.2) | 22 (2.5) | 0.026 |
| Chronic pulmonary disease | 143 (6.7) | 68 (5.4) | 75 (8.4) | 0.006 |
| Congestive heart failure | 19 (0.9) | 13 (1.0) | 6 (0.7) | 0.377 |
| Coronary atherosclerosis | 86 (4.0) | 47 (3.7) | 39 (4.4) | 0.462 |
| Depression | 88 (4.1) | 38 (3.0) | 50 (5.6) | 0.003 |
| Diabetes | 266 (12.4) | 156 (12.4) | 110 (12.3) | 0.953 |
| Dyslipidemia | 571 (26.6) | 322 (25.7) | 249 (27.9) | 0.237 |
| Hypertension | 531 (24.7) | 291 (23.2) | 240 (26.9) | 0.047 |
| Obesity | 88 (4.1) | 51 (4.1) | 37 (4.2) | 0.919 |
| Mild liver disease | 69 (3.2) | 45 (3.6) | 24 (2.7) | 0.248 |
| Moderate or severe liver disease | 3 (0.1) | 2 (0.2) | 1 (0.1) | 0.773 |
| Myocardial infarction | 15 (0.7) | 5 (0.4) | 10 (1.1) | 0.047 |
| Psoriatic arthritis | 277 (12.9) | 156 (12.4) | 121 (13.6) | 0.434 |
| Renal disease | 28 (1.3) | 17 (1.4) | 11 (1.2) | 0.809 |
| TI A/stroke | 32 (1.5) | 14 (1.1) | 18 (2.0) | 0.088 |
| Unstable angina | 8 (0.4) | 3 (0.2) | 5 (0.6) | 0.228 |
| Charlson Comorbidity Index | 0.180 | |||
| Mean (SD) | 0.4 (0.86) | 0.3 (0.83) | 0.4 (0.89) | - |
| Medications, n (%) | ||||
| Topicals | 1,758 (81.9) | 1,024 (81.6) | 734 (82.4) | 0.641 |
| Methotrexate | 518 (24.1) | 295 (23.5) | 223 (25.0) | 0.417 |
| Cyclosporine | 65 (3.0) | 39 (3.1) | 26 (2.9) | 0.801 |
| Acitretin | 198 (9.2) | 108 (8.6) | 90 (10.1) | 0.238 |
| Methoxsalen | 10 (0.5) | 5 (0.4) | 5 (0.6) | 0.585 |
| Phototherapy | 269 (12.5) | 157 (12.5) | 112 (12.6) | 0.967 |
| Provider specialty, n (%) | 0.354 | |||
| Primary care, internal medicine, general practice | 252 (11.7) | 144 (11.5) | 108 (12.1) | - |
| Dermatologist | 1,525 (71.1) | 906 (72.2) | 619 (69.5) | - |
| Rheum atolo gist | 81 (3.8) | 39 (3.1) | 42 (4.7) | - |
| Other | 221 (10.3) | 128 (10.2) | 93 (10.4) | - |
| Missing | 67 (3.1) | 38 (3.0) | 29 (3.3) | - |
| Concomitant medication use (post-index) | ||||
| Medication use, n (%) | ||||
| Topic a l s | 1,330 (62.0) | 733 (58.4) | 597 (67.0) | < 0.001 |
| Methotrexate | 272 (12.7) | 92 (7.3) | 180 (20.2) | < 0.001 |
| Cyclosporine | 40 (1.9) | 12 (1.0) | 28 (3.1) | < 0.001 |
| Acitretin | 68 (3.2) | 12 (1.0) | 56 (6.3) | < 0.001 |
| Concomitant phototherapy | 127 (5.9) | 67 (5.3) | 60 (6.7) | 0.177 |
aP value is from analysis of variance for continuous variables and chi-square test for categorical variables.
bSee Appendix for ICD-9-CM codes (available in online article).
ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; SD = standard deviation; TIA = transient ischemic attack.